KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Operating Leases: 2019-2024

Historic Operating Leases for BeOne Medicines (ONC) over the last 6 years, with Dec 2024 value amounting to $44.3 million.

  • BeOne Medicines' Operating Leases rose 58.34% to $51.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 58.34%. This contributed to the annual value of $44.3 million for FY2024, which is 0.17% up from last year.
  • Latest data reveals that BeOne Medicines reported Operating Leases of $44.3 million as of FY2024, which was up 0.17% from $44.2 million recorded in FY2023.
  • BeOne Medicines' 5-year Operating Leases high stood at $65.0 million for FY2021, and its period low was $43.3 million during FY2020.
  • Over the past 3 years, BeOne Medicines' median Operating Leases value was $44.3 million (recorded in 2024), while the average stood at $49.0 million.
  • As far as peak fluctuations go, BeOne Medicines' Operating Leases surged by 50.00% in 2021, and later dropped by 24.52% in 2023.
  • BeOne Medicines' Operating Leases (Yearly) stood at $43.3 million in 2020, then skyrocketed by 50.00% to $65.0 million in 2021, then dropped by 9.86% to $58.6 million in 2022, then fell by 24.52% to $44.2 million in 2023, then grew by 0.17% to $44.3 million in 2024.